The Effect of Topical Doxycycline on Corneal Neovascularization

References

• Folkman J. How blood vessels growth regulated in normal and neoplastic tissue?G.H.A. Clowes memorial award lecture. Cancer Res 1986;46:467–473
   PubMed Web of Science ®Google Scholar
• Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931–10934
   PubMed Web of Science ®Google Scholar
• Azar D. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing. Trans Am Ophthalmol Soc 2006;104:264–362 (An American Ophthalmological Society Thesis)
   PubMedGoogle Scholar
• Santos LN, de Moura LR, Fernades BF, Cheema DP, Burnier MN Jr. Histopathological study of delayed regraft after corneal graft failure. Cornea 2011;30:167–170
   PubMed Web of Science ®Google Scholar
• Lee P, Wang CC, Adamis AP. Ocular neovascularization: epidemiologic review. Surv Ophthalmol 1998;43:245–269
   PubMed Web of Science ®Google Scholar
• Taylor S, Folkman J. Protamin is an inhibitor of angiogenesis. Nature 1982;297:307–312
   PubMed Web of Science ®Google Scholar
• Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719–725
   PubMed Web of Science ®Google Scholar
• Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375–1378
   PubMed Web of Science ®Google Scholar
• Nikolic Lj, Friend J, Taylor S, Thoft RA. Inhibition of vascularization in rabbit corneas by heparin:cortisone pallets. Invest Ophthalmol Vis Sci 1986;27:449–456
   PubMedGoogle Scholar
• Haynes WL, Proia AD, Klintworth GK. Effects of inhibitors of arachidonic acid metabolism on corneal neovascularization in rats. Invest Ophthalmol Vis Sci 1989;30:1588–1593
   PubMed Web of Science ®Google Scholar
• Lipman RM, Epstein RJ. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992;110:405–407
   PubMed Web of Science ®Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–4085
   PubMed Web of Science ®Google Scholar
• Bock F, Onderka J, Ditrich T, Bachmann B, Kruse FE, Paschke M, et al. Bevacizumab is a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545–2552
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracycline inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998;12:12–26
   PubMedGoogle Scholar
• Raffeto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008;75:346–359
   PubMedGoogle Scholar
• Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharm Res 2011;63:102–107
   Google Scholar
• Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 1995;36:418–424
   PubMed Web of Science ®Google Scholar
• Aydin E, Kivilcim M, Peyman GA, Esfahani MR, Kazi AA, Sanders DR. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea 2008;27:446–453
   PubMed Web of Science ®Google Scholar
• Richardson M, Vong D, Lacroix S, Stanisz J, Singh G. Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM). Cancer Chemother Pharmacol 2009;56:1–9
   Google Scholar
• Azar DT, Casanova FH, Mimura T, Jain S, Zhou Z, Han KY, et al. Corneal epithelial MT1-MMP inhibits vascular endothelial cell proliferation and migration. Cornea 2010;29:321–330
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Palavali LH, Samuels Y. Protective role of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 2009;8:3657–3662
   PubMed Web of Science ®Google Scholar
• Solomon A, Rosenblatt M, Li D, Monroy D, Ji Z, Lokeshwar BL, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci 2000;41:2544–2557
   PubMed Web of Science ®Google Scholar
• Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D`Amato R, et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB 2008;22: 3728–3735
   PubMedGoogle Scholar
• Abelson MB, Udell IJ, Weston JH. Normal human tear pH by direct measurement. Arch Ophthalmol 1981;99:301
   PubMed Web of Science ®Google Scholar
• Carney LG, Mauger TF, Hill RM. Buffering in human tears: pH responses to acid and base challenge. Invest Ophthalmol Vis Sci 1989;30:747–754
   PubMed Web of Science ®Google Scholar
• Smith VA, Cook SD. Doxycycline – a role in ocular surface repair. Br J Ophthalmol 2004;88:619–625
   PubMed Web of Science ®Google Scholar
• Ashton N, Cook C, Langham M. Effect of cortisone on vascularisation and opacification of the cornea. Br J Ophthalmol 1951;35:718–724
   PubMed Web of Science ®Google Scholar
• Congdon NG, Schein OD, von Kulajta P, Lubowski LH, Gilbert Dkaty J. Corneal complications associated with topical ophthalmic use of nonsteroid antiinflamatory drugs. J Cat Ref Surg 2001;27:622–631
   PubMed Web of Science ®Google Scholar
• De Stefano J, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125:834–836
   PubMedGoogle Scholar
• Bock F, Koenig Y, Kruse F, Cursifen C. Bevacizumab (Avastin) eye drops inhibit corneal neovacularization. Graefes Arch Clin Exp Ophthal 2008;246:281–284
   PubMed Web of Science ®Google Scholar
• Kim SW, Ha BJ, Kim EK, Tcach H, Kim T. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33–8
   PubMed Web of Science ®Google Scholar
• Koenig Y, Bock F, Horn F, Kruse F, Straub K, Kursifen C. Short and long term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against cornal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1357–1382
   Google Scholar
• Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) versus bevacizumab (Avastin). Ocular Surf 2012;10:67–83
   PubMed Web of Science ®Google Scholar
• Dastherdi MH, Al-Arafaj KM, Nallasany N, Pineda R, Pavan-Langston D, Dana R. Topical bevacizumab in the treatment of corneal neovascularization; results of a prospective, open-label, non-comparative study. Arch Ophthalmol 2009;127:381–389
   PubMedGoogle Scholar
• Kim EC, Riu HW, Lee HJ, Kim MS. Bevacizumab eye drops delay corneal epithelial healing and increase the stromal response to epithelial injury in rats. Clin Exp Ophthalmol. DOI 10.111/ceo.12085
   Google Scholar
• Su W, Li Z, Li Y, Lin M, Yao L, Liu Y, et al. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects. Invest Ophthalmol Vis Sci 2011;52:9108–9115
   PubMed Web of Science ®Google Scholar